Nicolas Chapuis

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore et al. · Cell · 2020 · 898 citations · Full text

Mild Covid-19, Hematological Malignancy, Hematology +5

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

Lise Willems, Nathalie Jacque, Arnaud Jacquel et al. · Blood · 2013 · 279 citations · Full text

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways

Jérôme Tamburini, Nicolas Chapuis, Valérie Bardet et al. · Blood · 2007 · 252 citations

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

Alexa S. Green, Nicolas Chapuis, Thiago Trovati Maciel et al. · Blood · 2010 · 194 citations · Full text

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

Sophie Park, Nicolas Chapuis, Valérie Bardet et al. · Leukemia · 2008 · 190 citations

Dual Inhibitor, Hematological Malignancy, Medicine +11